Peptide mimotopes of oncoproteins as therapeutic agents in breast cancer.

B. T. Ashok, L. David, Y. G. Chen, V. P. Garikapaty, B. Chander, D. Kanduc, A. Mittelman, R. K. Tiwari

Research output: Contribution to journalArticle

Abstract

Generation of an immune response to oncoproteins can lead to a cancer specific protective immunity. Several such oncoproteins are being examined as tumor targets with mixed results. We are evaluating the clinical utility of synthetic peptides that would mimic the antigen immunologically and elicit a tumor specific immune response. HER-2/neu, an oncoprotein whose expression in breast cancer is associated with poor prognosis, lower disease free-survival and a propensity for metastases was chosen as a model. Antibodies, Ab2, Ab4 and Ab5 directed towards the extracellular domain of HER-2/neu were reacted to peptides from two synthetic phage display peptide libraries, LX-8 (12-mer peptide library containing disulfide bridge) and X-15 (linear 15-mer). The isolated peptides were sequenced and characterized for ability to produce high titer antibodies and cross-reactivity. The peptides isolated did not show any sequence homology to protein databases but did show a hierarchy of immunogenic epitopes. Antibodies generated against peptides selected against the same antibody Ab2 or Ab4 showed affinity variation. Phages selected against Ab2 were also able to compete with binding of Ab2 to HER-2/neu. These results validate our hypothesis that synthetic peptides that mimic the antigenic epitope of oncoprotein can be generated and their clinical utility rests on devising a screening mechanism to identify peptides that can elicit an immune response directed to the oncoprotein and if possible its antigenic variants.

Original languageEnglish (US)
Pages (from-to)465-471
Number of pages7
JournalInternational Journal of Molecular Medicine
Volume11
Issue number4
StatePublished - Apr 2003
Externally publishedYes

Fingerprint

Oncogene Proteins
Breast Neoplasms
Peptides
Peptide Library
Antibodies
Therapeutics
Epitopes
Neoplasms
Protein Databases
Sequence Homology
Disulfides
Bacteriophages
Disease-Free Survival
Immunity
Neoplasm Metastasis
Antigens

ASJC Scopus subject areas

  • Genetics

Cite this

Ashok, B. T., David, L., Chen, Y. G., Garikapaty, V. P., Chander, B., Kanduc, D., ... Tiwari, R. K. (2003). Peptide mimotopes of oncoproteins as therapeutic agents in breast cancer. International Journal of Molecular Medicine, 11(4), 465-471.

Peptide mimotopes of oncoproteins as therapeutic agents in breast cancer. / Ashok, B. T.; David, L.; Chen, Y. G.; Garikapaty, V. P.; Chander, B.; Kanduc, D.; Mittelman, A.; Tiwari, R. K.

In: International Journal of Molecular Medicine, Vol. 11, No. 4, 04.2003, p. 465-471.

Research output: Contribution to journalArticle

Ashok, BT, David, L, Chen, YG, Garikapaty, VP, Chander, B, Kanduc, D, Mittelman, A & Tiwari, RK 2003, 'Peptide mimotopes of oncoproteins as therapeutic agents in breast cancer.', International Journal of Molecular Medicine, vol. 11, no. 4, pp. 465-471.
Ashok BT, David L, Chen YG, Garikapaty VP, Chander B, Kanduc D et al. Peptide mimotopes of oncoproteins as therapeutic agents in breast cancer. International Journal of Molecular Medicine. 2003 Apr;11(4):465-471.
Ashok, B. T. ; David, L. ; Chen, Y. G. ; Garikapaty, V. P. ; Chander, B. ; Kanduc, D. ; Mittelman, A. ; Tiwari, R. K. / Peptide mimotopes of oncoproteins as therapeutic agents in breast cancer. In: International Journal of Molecular Medicine. 2003 ; Vol. 11, No. 4. pp. 465-471.
@article{cedf8c0a9acf4bb48e7266489c4d329e,
title = "Peptide mimotopes of oncoproteins as therapeutic agents in breast cancer.",
abstract = "Generation of an immune response to oncoproteins can lead to a cancer specific protective immunity. Several such oncoproteins are being examined as tumor targets with mixed results. We are evaluating the clinical utility of synthetic peptides that would mimic the antigen immunologically and elicit a tumor specific immune response. HER-2/neu, an oncoprotein whose expression in breast cancer is associated with poor prognosis, lower disease free-survival and a propensity for metastases was chosen as a model. Antibodies, Ab2, Ab4 and Ab5 directed towards the extracellular domain of HER-2/neu were reacted to peptides from two synthetic phage display peptide libraries, LX-8 (12-mer peptide library containing disulfide bridge) and X-15 (linear 15-mer). The isolated peptides were sequenced and characterized for ability to produce high titer antibodies and cross-reactivity. The peptides isolated did not show any sequence homology to protein databases but did show a hierarchy of immunogenic epitopes. Antibodies generated against peptides selected against the same antibody Ab2 or Ab4 showed affinity variation. Phages selected against Ab2 were also able to compete with binding of Ab2 to HER-2/neu. These results validate our hypothesis that synthetic peptides that mimic the antigenic epitope of oncoprotein can be generated and their clinical utility rests on devising a screening mechanism to identify peptides that can elicit an immune response directed to the oncoprotein and if possible its antigenic variants.",
author = "Ashok, {B. T.} and L. David and Chen, {Y. G.} and Garikapaty, {V. P.} and B. Chander and D. Kanduc and A. Mittelman and Tiwari, {R. K.}",
year = "2003",
month = "4",
language = "English (US)",
volume = "11",
pages = "465--471",
journal = "International Journal of Molecular Medicine",
issn = "1107-3756",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Peptide mimotopes of oncoproteins as therapeutic agents in breast cancer.

AU - Ashok, B. T.

AU - David, L.

AU - Chen, Y. G.

AU - Garikapaty, V. P.

AU - Chander, B.

AU - Kanduc, D.

AU - Mittelman, A.

AU - Tiwari, R. K.

PY - 2003/4

Y1 - 2003/4

N2 - Generation of an immune response to oncoproteins can lead to a cancer specific protective immunity. Several such oncoproteins are being examined as tumor targets with mixed results. We are evaluating the clinical utility of synthetic peptides that would mimic the antigen immunologically and elicit a tumor specific immune response. HER-2/neu, an oncoprotein whose expression in breast cancer is associated with poor prognosis, lower disease free-survival and a propensity for metastases was chosen as a model. Antibodies, Ab2, Ab4 and Ab5 directed towards the extracellular domain of HER-2/neu were reacted to peptides from two synthetic phage display peptide libraries, LX-8 (12-mer peptide library containing disulfide bridge) and X-15 (linear 15-mer). The isolated peptides were sequenced and characterized for ability to produce high titer antibodies and cross-reactivity. The peptides isolated did not show any sequence homology to protein databases but did show a hierarchy of immunogenic epitopes. Antibodies generated against peptides selected against the same antibody Ab2 or Ab4 showed affinity variation. Phages selected against Ab2 were also able to compete with binding of Ab2 to HER-2/neu. These results validate our hypothesis that synthetic peptides that mimic the antigenic epitope of oncoprotein can be generated and their clinical utility rests on devising a screening mechanism to identify peptides that can elicit an immune response directed to the oncoprotein and if possible its antigenic variants.

AB - Generation of an immune response to oncoproteins can lead to a cancer specific protective immunity. Several such oncoproteins are being examined as tumor targets with mixed results. We are evaluating the clinical utility of synthetic peptides that would mimic the antigen immunologically and elicit a tumor specific immune response. HER-2/neu, an oncoprotein whose expression in breast cancer is associated with poor prognosis, lower disease free-survival and a propensity for metastases was chosen as a model. Antibodies, Ab2, Ab4 and Ab5 directed towards the extracellular domain of HER-2/neu were reacted to peptides from two synthetic phage display peptide libraries, LX-8 (12-mer peptide library containing disulfide bridge) and X-15 (linear 15-mer). The isolated peptides were sequenced and characterized for ability to produce high titer antibodies and cross-reactivity. The peptides isolated did not show any sequence homology to protein databases but did show a hierarchy of immunogenic epitopes. Antibodies generated against peptides selected against the same antibody Ab2 or Ab4 showed affinity variation. Phages selected against Ab2 were also able to compete with binding of Ab2 to HER-2/neu. These results validate our hypothesis that synthetic peptides that mimic the antigenic epitope of oncoprotein can be generated and their clinical utility rests on devising a screening mechanism to identify peptides that can elicit an immune response directed to the oncoprotein and if possible its antigenic variants.

UR - http://www.scopus.com/inward/record.url?scp=0037553350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037553350&partnerID=8YFLogxK

M3 - Article

C2 - 12632099

AN - SCOPUS:0037553350

VL - 11

SP - 465

EP - 471

JO - International Journal of Molecular Medicine

JF - International Journal of Molecular Medicine

SN - 1107-3756

IS - 4

ER -